Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The informed consent form must be signed before any study specific tests or procedures are done~* Male or female patients aged 18 years and older at the first screening visit~* Histologically confirmed diagnosis of advanced or metastatic non adipocyte soft tissue sarcoma (STS)~* Suitable for treatment with pazopanib in an in-label prescription~* Patients with a life expectancy of at least 6 months~* Eastern Co-operative Oncology Group (ECOG) performance status 0-2~* Adequate organ function as given in Table 1~* For patients with previous anthracycline therapy a normal heart function needs to be documented with an left ventricular ejection fraction (LVEF) of minimal 50% (echocardiogram)~* Patients must be willing and able to fill in the Quality of live (QoL) questionnaires using a tablet PC~* Ability to understand and follow study-related instructions~* Confirmation of the subject's health insurance coverage prior to the first visit~Exclusion Criteria:~* Pretreatment with pazopanib~* Contraindications according to the local Summary of product characteristics ( SmPC) of Votrient®~* Patients having to following STS specific tumors~  * adipocyte sarcoma including all subtypes,~ * all rhabdomyosarcoma, which are not alveolar or pleomorph~ * Chondrosarcoma~ * Osteosarcoma~ * Ewing-tumors, i.e. primitive neuroectodermal tumors (PNET), gastrointestinal stromal tumor (GIST)~ * Dermatofibrosarcoma protuberans~ * inflammatory myofibroblastic sarcoma~ * Malignant mesothelioma~ * Mixed mesenchymal and epidermal tumors of the uterus Other malignant underlying diseases with the exception of the following:~ * Free of disease for at least 3 years~ * Completely resected, non-melanoma skin cancer~ * Successfully treated carcinoma in situ~ * Patients with metastases of the central nervous system (CNS) at screening, which are asymptomatic AND do not require treatment with steroids or enzyme-inducing anticonvulsant drugs~ * Patients with metastases of the CNS, which are already treated (operation and/or radiotherapy, radiosurgery or gamma-knife)~* Major surgery or trauma within 28 days before the first dose of study medication and / or presence of a non-healing wound, fracture, or ulcer~* Clinical indications of an active bleeding or a bleeding diathesis~* Known endobronchial lesions or lesions that infiltrate the large pulmonary artery~* Hemoptysis of\> 2.5 mL within 8 weeks before the first dose of study drug~* Existing uncontrolled infection~* Heart rate-corrected QT-time according to the Fridericia's-formula (QTcF) 450 ms in males and 460 ms in females~* History of one or more of the following cardiovascular diseases within the last 6 months:~  * Cardiac angioplasty or coronary stent~ * Myocardial infarction~ * Unstable angina pectoris~ * Coronary artery bypass surgery~ * Symptomatic peripheral arterial disease~* Cardiac insufficiency New York Heart Association (NYHA) functional dass III or IV~* Poorly controlled hypertension defined as systolic blood pressure 140 mmHg or diastolic blood pressure 90 mmHg~* History of cerebrovascular disease, including transient ischemic attacks (TIA), pulmonary embolism or untreated deep vein thrombosis within 6 months prior to study entry. Patients with deep vein thrombosis who have received therapeutic anticoagulation for a minimum of 6 weeks might be included in the study.~* Clinically significant gastrointestinal changes that increase the risk of gastrointestinal bleeding~* Clinically significant gastrointestinal changes that may affect the absorption of the study drugs~* Treatment with any of the following anti-neoplastic therapies:~  * Irradiation or Tumor embolization within 14 days prior to the first dose of study drug~ * Chemotherapy, immunotherapy, biological therapy, study medication or hormonal therapy within 14 days or 5 half lives of substance (whichever is langer) prior to the first dose of study drug~* If the discontinuation of prohibited medication (see Section 6.9) at least 14 days or 5 half-lives of substance (whichever is langer) prior to the first dose of pazopanib is medically not acceptable or refused by the patient~* A history of hypersensitivity to any of the study drugs or their ingredients or to drugs with similar chemical structure~* Addiction or other diseases that preclude the patient from appropriately assessing the nature and scope as well as possible consequences of the clinical trial~* Pregnant or breast-feeding women~* Women of childbearing potential unless women who meet the following criteria:~  * Post-menopausal (12 months natural amenorrhea without any application of a hormonal contraceptive or hormonal substitution therapy))~ * Postoperatively (6 weeks after bilateral ovariectomy with or without hysterectomy)~ * Regular and correct use of a contraceptive method with error rate \<1% per year such as implants, depot injections, oral contraceptives or intrauterine devices during treatment and up 6 months after end of treatment~ * Sexual abstinence~ * Vasectomy of the partner~* Men of sexual activity with women of childbearing potential who are not willing to use an effective barrier method of contraception during and up to 6 months after the end of therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib (Type: EXPERIMENTAL): Pazopanib; 800 mg; daily; oral
- Chemotherapy (Type: ACTIVE_COMPARATOR): Guideline-conform chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).